$CDNA
CareDx, Inc. Stock $cdna

$cdna Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000119312515287911 Filed on August 12, 2015

Income Statement

Concept	2015 Q2	2014 Q2	2014 Q1
Revenue	$7.129M	$6.776M	$5.924M
YoY Change	5.21%	24.17%	18.93%
Cost Of Revenue	$2.508M	$2.403M	$2.162M
YoY Change	4.37%	13.4%	1.98%
Gross Profit	$4.621M	$4.373M	$3.762M
YoY Change	5.67%	31.01%	31.54%
Gross Profit Margin	64.82%	64.54%	63.5%
Selling, General & Admin	$4.855M	$3.926M	$3.269M
YoY Change	23.66%	42.87%	24.3%
% of Gross Profit	105.06%	89.78%	86.9%
Research & Development	$2.510M	$792.0K	$720.0K
YoY Change	216.92%	-6.38%	-28.0%
% of Gross Profit	54.32%	18.11%	19.14%
Depreciation & Amortization	$190.0K	$110.0K	$106.0K
YoY Change	72.73%	-35.29%	-119.63%
% of Gross Profit	4.11%	2.52%	2.82%
Operating Expenses	$10.02M	$7.121M	$6.151M
YoY Change	40.64%	24.65%	68.98%
Operating Profit	-$2.886M	-$345.0K	-$227.0K
YoY Change	736.52%	34.77%	-70.9%
Interest Expense	-$260.0K	-$640.0K	-$550.0K
YoY Change	-59.38%	18.52%	-3.51%
% of Operating Profit
Other Income/Expense, Net	-$43.00K	$366.0K	-$529.0K
YoY Change	-111.75%	-7420.0%	5190.0%
Pretax Income	-$3.185M	-$623.0K	-$1.300M
YoY Change	411.24%	-22.32%	-3.7%
Income Tax	$0.00	-$1.500M	$0.00
% Of Pretax Income
Net Earnings	-$3.185M	$877.0K	-$1.304M
YoY Change	-463.17%	-209.35%	-3.26%
Net Earnings / Revenue	-44.68%	12.94%	-22.01%
Basic Earnings Per Share	-$0.27	$0.87	-$1.29
Diluted Earnings Per Share	-$0.27	$0.13	-$1.29
COMMON SHARES
Basic Shares Outstanding	11.84M	1.013M	1.012M
Diluted Shares Outstanding	11.84M	6.940M	1.012M

Balance Sheet

Concept	2015 Q2	2014 Q2	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.90M	$7.900M	$4.800M
YoY Change	367.09%
Cash & Equivalents	$36.89M	$7.872M	$5.128M
Short-Term Investments
Other Short-Term Assets	$700.0K	$3.300M	$1.800M
YoY Change	-78.79%
Inventory	$731.0K	$614.0K	$700.0K
Prepaid Expenses
Receivables	$1.700M	$1.700M	$2.100M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$40.01M	$13.53M	$9.500M
YoY Change	195.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.559M	$1.665M	$1.500M
YoY Change	53.69%
Goodwill	$12.01M	$12.01M
YoY Change	0.0%
Intangibles	$6.650M	$6.650M
YoY Change	0.0%
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$100.0K
YoY Change
Total Long-Term Assets	$21.36M	$20.47M	$1.600M
YoY Change	4.37%
TOTAL ASSETS
Total Short-Term Assets	$40.01M	$13.53M	$9.500M
Total Long-Term Assets	$21.36M	$20.47M	$1.600M
Total Assets	$61.37M	$34.00M	$11.10M
YoY Change	80.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.203M	$1.741M	$800.0K
YoY Change	-30.9%
Accrued Expenses	$4.200M	$5.600M	$1.600M
YoY Change	-25.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.380M	$10.43M	$5.500M
YoY Change	-77.19%
Total Short-Term Liabilities	$8.242M	$21.21M	$10.60M
YoY Change	-61.15%
LONG-TERM LIABILITIES
Long-Term Debt	$13.39M	$8.338M	$10.60M
YoY Change	60.58%
Other Long-Term Liabilities	$28.00K	$5.100M	$6.600M
YoY Change	-99.45%
Total Long-Term Liabilities	$13.42M	$8.338M	$17.20M
YoY Change	60.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.242M	$21.21M	$10.60M
Total Long-Term Liabilities	$13.42M	$8.338M	$17.20M
Total Liabilities	$24.59M	$35.46M	$27.80M
YoY Change	-30.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$164.8M	-$160.6M
YoY Change	2.65%
Common Stock	$12.00K	$1.000K
YoY Change	1100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$36.77M	-$150.9M	-$16.70M
YoY Change
Total Liabilities & Shareholders Equity	$61.37M	$34.00M	$11.10M
YoY Change	80.5%

Cashflow Statement

Concept	2015 Q2	2014 Q2	2014 Q1
OPERATING ACTIVITIES
Net Income	-$3.185M	$877.0K	-$1.304M
YoY Change	-463.17%	-209.35%	-3.26%
Depreciation, Depletion And Amortization	$190.0K	$110.0K	$106.0K
YoY Change	72.73%	-35.29%	-119.63%
Cash From Operating Activities	-$1.740M	$850.0K	$180.0K
YoY Change	-304.71%	-342.86%	-98.23%
INVESTING ACTIVITIES
Capital Expenditures	-$370.0K	-$140.0K	$19.00K
YoY Change	164.29%	250.0%	-96.04%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$380.0K
YoY Change	-100.0%
Cash From Investing Activities	-$370.0K	-$520.0K	-$20.00K
YoY Change	-28.85%	1200.0%	-100.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	2.700M	-450.0K
YoY Change	-99.63%	-27100.0%	-98.1%
NET CHANGE
Cash From Operating Activities	-1.740M	850.0K	180.0K
Cash From Investing Activities	-370.0K	-520.0K	-20.00K
Cash From Financing Activities	10.00K	2.700M	-450.0K
Net Change In Cash	-2.100M	3.030M	-290.0K
YoY Change	-169.31%	-857.5%	-83.98%
FREE CASH FLOW
Cash From Operating Activities	-$1.740M	$850.0K	$180.0K
Capital Expenditures	-$370.0K	-$140.0K	$19.00K
Free Cash Flow	-$1.370M	$990.0K	$161.0K
YoY Change	-238.38%	-419.35%	-98.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11887409	shares
CY2014Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	239000
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7872000
CY2014Q2	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	120000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1515154	shares
CY2015Q1	us-gaap	Share Price SharePrice	5.56
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100133900	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.03
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11838794	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11838794	shares
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Share Price SharePrice	6.48
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1515154	shares
CY2015Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1840000
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	646000
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2051000
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	36773000
CY2015Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13389000
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28000
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	113000
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	201595000
CY2015Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	230000
CY2015Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	963000
CY2015Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1554000
CY2015Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2380000
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	500000
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1203000
CY2015Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	963000
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-164834000
CY2015Q2	us-gaap	Liabilities Liabilities	24593000
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61366000
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	417000
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	12000
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8242000
CY2015Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	268000
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2015Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	62000
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3700000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2146000
CY2015Q2	us-gaap	Assets Assets	61366000
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6650000
CY2015Q2	us-gaap	Inventory Net InventoryNet	731000
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	147000
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2559000
CY2015Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	1706000
CY2015Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	343000
CY2015Q2	us-gaap	Assets Current AssetsCurrent	40005000
CY2015Q2	us-gaap	Goodwill Goodwill	12005000
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	674000
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36894000
CY2015Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	388000
CY2015Q2	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	383000
CY2015Q2	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	396000
CY2015Q2	cdna	Royalty Revenue Receivable RoyaltyRevenueReceivable	179000
CY2015Q2	cdna	Accrued Over Payments And Refunds AccruedOverPaymentsAndRefunds	117000
CY2015Q2	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	576815	shares
CY2015Q2	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue	1750000
CY2015Q2	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	938339	shares
CY2015Q2	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	289000
CY2015Q2	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	8.20
CY2015Q2	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent	176000
CY2015Q2	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Non Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent	214000
CY2014Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	525000
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5128000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1031804	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.36
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11803970	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11803970	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1616000
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	463000
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1684000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	41298000
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5451000
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28000
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	273000
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	200661000
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	202000
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1074000
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1684000
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5961000
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1074000
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	505000
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1128000
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	70000
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25000
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-159375000
CY2014Q4	us-gaap	Assets Assets	61141000
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6650000
CY2014Q4	us-gaap	Inventory Net InventoryNet	686000
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	147000
CY2014Q4	us-gaap	Liabilities Liabilities	19843000
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61141000
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	471000
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	12000
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11135000
CY2014Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	241000
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1968000
CY2014Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2687000
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	277000
CY2014Q4	us-gaap	Assets Current AssetsCurrent	40346000
CY2014Q4	us-gaap	Goodwill Goodwill	12005000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	542000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36431000
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	409000
CY2014Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	318000
CY2014Q4	cdna	Royalty Revenue Receivable RoyaltyRevenueReceivable	54000
CY2014Q4	cdna	Accrued Over Payments And Refunds AccruedOverPaymentsAndRefunds	146000
CY2014Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	144000
CY2014Q4	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent	76000
CY2014Q4	cdna	Debt Issuance And Discount Component Of Recognized Debt Liability Non Current DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent	11000
CY2015Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	20000000
CY2015Q1	cdna	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	90000
CY2014Q3	cdna	Sale Of Stock Pursuant To Exercise Of Underwriters Over Allotment Option SaleOfStockPursuantToExerciseOfUnderwritersOverAllotmentOption	220000	shares
CY2015Q1	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.0200	pure
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	1033000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M6D
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0170	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7812652	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4184	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1012769	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1012769	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	164000
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	1827000
	us-gaap	Net Income Loss NetIncomeLoss	-427000
	us-gaap	Revenues Revenues	12700000
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	119000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1192000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	376000
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	156000
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	12544000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	909000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-572000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	96000
	us-gaap	Licenses Revenue LicensesRevenue	31200
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-163000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-545000
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	1000
	us-gaap	Royalty Revenue RoyaltyRevenue	117000
	us-gaap	Embedded Derivative Gain On Embedded Derivative EmbeddedDerivativeGainOnEmbeddedDerivative	118000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1927000
	us-gaap	Reimbursement Revenue ReimbursementRevenue	16200
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-427000
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	2152000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1500000
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	4982000
	us-gaap	Share Based Compensation ShareBasedCompensation	185000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	283000
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	15000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3084000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	349000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2117000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2744000
	us-gaap	Operating Expenses OperatingExpenses	13272000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-540000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2251000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1512000
	us-gaap	Cost Of Services CostOfServices	4565000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	185000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4111000
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-196000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1123000
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	721000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	222000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Other Noncash Income Tax Expense OtherNoncashIncomeTaxExpense	-1500000
	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	23000
	cdna	Interest On Subordinated Convertible Note Net Of Gain On Change In Fair Value Of Derivative Related To Subordinated Convertible Note InterestOnSubordinatedConvertibleNoteNetOfGainOnChangeInFairValueOfDerivativeRelatedToSubordinatedConvertibleNote	0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2747000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Debt Instrument Description Of Variable Rate Basis DebtInstrumentDescriptionOfVariableRateBasis	Draw A and Draw B each bear interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender.
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0187	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	23844	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	20291	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2204050	shares
	us-gaap	Debt Instrument Date Of First Required Payment1 DebtInstrumentDateOfFirstRequiredPayment1	2016-01-01
	us-gaap	Debt Instrument Description DebtInstrumentDescription	The Company agreed to issue to the lender detachable warrants to purchase shares of the Company's common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001217234
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-12-01
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
	us-gaap	Additional Cash And Cash Equivalent Related Text AdditionalCashAndCashEquivalentRelatedText	Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Concentrations of Credit Risk and Other Risks and Uncertainties</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. For the six months ended June 30, 2015 and 2014, approximately 50% and 49%, respectively, of testing revenue was derived from Medicare. No other payers represented more than 10% of testing revenue for these periods. At June 30, 2015 and December 31, 2014 approximately 40% and 78%, respectively, of accounts receivable was from Medicare. No other payer represented more than 10% of accounts receivable at June 30, 2015 and December 31, 2014.</p> </div>
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-111000
	us-gaap	Line Of Credit Facility Initiation Date1 LineOfCreditFacilityInitiationDate1	2015-01-30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4085	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.74
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	CareDx, Inc.
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11824993	shares
	us-gaap	Default Longterm Debt Description Of Violation Or Event Of Default DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault	Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	525078	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.35
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11824993	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.62
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Collaboration and License Revenue</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company’s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis.</p> </div>
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>Use of Estimates</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i) revenue recognition, (ii) the differences between amounts billed and estimated receipts from payers, (iii) the determination of the accruals for clinical studies, (iv) the determination of refunds to be requested by third-party payers, (v) the fair value of assets and liabilities, (vi) the valuation of warrants to purchase convertible preferred stock, (vii) the determination of fair value of the Company’s common stock, (viii) the fair value of contingent consideration in a business acquisition, (ix) the fair value of the embedded features associated with the subordinated convertible note, (x) the fair value of the embedded features associated with long-term debt, (xi) measurement of stock-based compensation expense, (xii) the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xiii) any impairment of long-lived assets including in-process technology and goodwill and (xiv) legal contingencies. Actual results could differ from those estimates.</p> </div>
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	17884	shares
	dei	Trading Symbol TradingSymbol	CDNA
	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	Principal pay-down of the loan begins on January 1, 2016 with the loan being payable in 36 equal monthly installments. The principal pay-down of the loan may be delayed to July 1, 2016 with the loan being payable in 30 equal monthly installments, if on December 31, 2015, the Company has achieved certain net product revenue milestones as described in the Loan Agreement.
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y2M12D
	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Name NewAccountingPronouncementOrChangeInAccountingPrincipleName	ASU 2015-03
	us-gaap	Net Income Loss NetIncomeLoss	-5457000
	us-gaap	Revenues Revenues	14344000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1083000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	733000
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	11724000
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	205000
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	14139000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4277000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	45000
	us-gaap	Licenses Revenue LicensesRevenue	0
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-97000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-981000
	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	33000
	us-gaap	Royalty Revenue RoyaltyRevenue	179000
	us-gaap	Embedded Derivative Gain On Embedded Derivative EmbeddedDerivativeGainOnEmbeddedDerivative	0
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5457000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-5457000
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	108000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	15625000
	us-gaap	Share Based Compensation ShareBasedCompensation	692000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4549000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	450000
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	274000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	463000
	us-gaap	Operating Expenses OperatingExpenses	18621000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-733000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3943000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3931000
	us-gaap	Cost Of Services CostOfServices	5218000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-111000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	692000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5034000
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	367000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-116000
	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	27000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	358000
	us-gaap	Other Noncash Income Tax Expense OtherNoncashIncomeTaxExpense	0
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P9Y3M18D
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodFairValue	123000
	cdna	Description Of Agreement Expected Expiration Year DescriptionOfAgreementExpectedExpirationYear	The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
	cdna	Percentage Of Default Interest Payment PercentageOfDefaultInterestPayment	0.05	pure
	cdna	Prepayment Penalty PrepaymentPenalty	0	pure
	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	59000
	cdna	Number Of Commercial Tests NumberOfCommercialTests	1	CommercialTests
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P7Y4M28D
	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	5.14
	cdna	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
	cdna	Interest On Subordinated Convertible Note Net Of Gain On Change In Fair Value Of Derivative Related To Subordinated Convertible Note InterestOnSubordinatedConvertibleNoteNetOfGainOnChangeInFairValueOfDerivativeRelatedToSubordinatedConvertibleNote	0
	cdna	Shelf Registration Date Of Filing ShelfRegistrationDateOfFiling	2015-08-10
	cdna	Stock Offering Costs Commissions Percentage StockOfferingCostsCommissionsPercentage	0.03	pure
CY2013Q2	cdna	Potential Refundable Portion Of Upfront Payment PotentialRefundablePortionOfUpfrontPayment	250000
CY2013Q2	cdna	Potential Refundable Portion Of Upfront Payment PotentialRefundablePortionOfUpfrontPayment	344000
CY2013Q2	cdna	Upfront Payment In Cash UpfrontPaymentInCash	387500
CY2013Q2	cdna	Upfront Payment In Cash UpfrontPaymentInCash	503000
CY2013Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	467000
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Instruments Classified In Shareholders Equity Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityPeriodIncreaseDecrease	-539000
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-1464000
CY2014	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	2552000
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	792000
CY2014Q2	us-gaap	Cost Of Services CostOfServices	2403000
CY2012	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	250000
CY2012	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	1000000
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	8663	shares
CY2015Q1	cdna	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodFairValue	48000
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M18D
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	189726	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0174	pure
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1092966	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	5355280	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4218	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6939568	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	381434	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1013128	shares
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	877000
CY2014Q2	us-gaap	Revenues Revenues	6776000
CY2014Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	119000
CY2014Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-644000
CY2014Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	66000
CY2014Q2	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	6710000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-345000
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	1800
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	366000
CY2014Q2	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	1000
CY2014Q2	us-gaap	Royalty Revenue RoyaltyRevenue	59000
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-623000
CY2014Q2	us-gaap	Reimbursement Revenue ReimbursementRevenue	1800
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	892000
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1500000
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-245000
CY2014Q2	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	0
CY2014Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1610000
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	7121000
CY2014Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	137000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2316000
CY2014Q2	cdna	Interest On Subordinated Convertible Note Net Of Gain On Change In Fair Value Of Derivative Related To Subordinated Convertible Note InterestOnSubordinatedConvertibleNoteNetOfGainOnChangeInFairValueOfDerivativeRelatedToSubordinatedConvertibleNote	15000
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2510000
CY2015Q2	us-gaap	Cost Of Services CostOfServices	2508000
CY2015Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	142000
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	411000
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2329000
CY2015Q2	cdna	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodFairValue	75000
CY2015Q2	cdna	Interest On Subordinated Convertible Note Net Of Gain On Change In Fair Value Of Derivative Related To Subordinated Convertible Note InterestOnSubordinatedConvertibleNoteNetOfGainOnChangeInFairValueOfDerivativeRelatedToSubordinatedConvertibleNote	0
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0169	pure
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	11628	shares
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2204050	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.4004	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11835405	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11835405	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.10
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-3185000
CY2015Q2	us-gaap	Revenues Revenues	7129000
CY2015Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-256000
CY2015Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	85000
CY2015Q2	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	7044000
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2886000
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-43000
CY2015Q2	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	16000
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	89000
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3185000
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3185000
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2015Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2526000
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	10015000

Files In Submission

Name	View Source	Status
0001193125-15-287911-index-headers.html	Edgar Link	pending
0001193125-15-287911-index.html	Edgar Link	pending
0001193125-15-287911.txt	Edgar Link	pending
0001193125-15-287911-xbrl.zip	Edgar Link	pending
cdna-20150630.xml	Edgar Link	completed
cdna-20150630.xsd	Edgar Link	pending
cdna-20150630_cal.xml	Edgar Link	unprocessable
cdna-20150630_def.xml	Edgar Link	unprocessable
cdna-20150630_lab.xml	Edgar Link	unprocessable
cdna-20150630_pre.xml	Edgar Link	unprocessable
d933029d10q.htm	Edgar Link	pending
d933029dex311.htm	Edgar Link	pending
d933029dex312.htm	Edgar Link	pending
d933029dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDNA
CareDx, Inc. Stock $cdna

2015 Q2 Form 10-Q Financial Statement

#000119312515287911 Filed on August 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA CareDx, Inc. Stock $cdna

2015 Q2 Form 10-Q Financial Statement

#000119312515287911 Filed on August 12, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA
CareDx, Inc. Stock $cdna